Product Wiki · Recalls · EU Safety Gate (RAPEX)

LIMITLESS — recall A12/03459/24

EU Safety Gate (RAPEX) · Slovenia · 2024-12-06 · Serious risk

Machine-translated with AI — the facts come from the issuing authority’s own notice (linked on this page); this language version was translated automatically by an AI model and is not reviewed. The original-language notice is authoritative. How we use AI →
Agency
EU Safety Gate (RAPEX)
Recall identifier
A12/03459/24
Date of alert
2024-12-06
Country / jurisdiction
Slovenia
Risk level
Serious risk
Risk type
Chemical
Brand
World Famous Tattoo Ink
Product category
Chemical products
Product type
Tattoo ink
Barcode (EAN/GTIN)
840058816846
Reported risk: Izdelek ima prekomerno koncentracijo svinca (izmerjena vrednost do 0,99 mg/kg). Svinec je škodljiv za zdravje ljudi, se kopiči v telesu in lahko vpliva na dojene ali nerojene otroke. Izdelek ni v skladu z Uredbo REACH.
Action taken by the authority
Type of economic operator taking notified measure
Distributor
Category of measure
Withdrawal of the product from the market
Date of entry into force
21/10/2024
Machine translation. This page was translated automatically from the English record we hold of the issuing authority’s notice. The English original is shown below and the authority’s own notice is linked above — both take precedence over this translation.

Product Name (original English): LIMITLESS

Risk Description (original English): The product has an excessive concentration of lead (measured value up to 0.99 mg/kg). Lead is harmful to human health, accumulates in the body, and may affect breast-fed or unborn children.

Primary source: https://ec.europa.eu/safety-gate-alerts/screen/webReport/alertDetail/10092317

Verify each fact at the issuing agency before acting. Recall scope, affected lots, and remediation instructions may be updated by the agency after our last sync.

ProductGuru indexes recall and safety-alert records from ~30 public agency registries. We are not lawyers, regulators or product-safety consultants. This page restates what the named agency published; consult the primary source above (or qualified counsel in your jurisdiction) before any commercial, medical or safety decision.